HCAT Stock Recent News

SALT LAKE CITY , July 18, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company") (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has entered into a five-year term loan facility for up to  $225,000,000 (the "Credit Facility" or the "Financing") with Silver Point Finance, the direct lending business of Silver Point Capital, L.P.  The Financing consists of (i) an initial term loan facility in an aggregate principal amount of $125,000,000 (the "Initial Facility") and (ii) a delayed draw term loan facility (the "Delayed Draw Facility") in an aggregate principal amount of $100,000,000.

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.

SALT LAKE CITY , June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Oncology providers and life science researchers use Carevive's flagship platform and/or Carevive data in routine clinical practice for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and/or post-treatment care.

SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences:

Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SALT LAKE CITY , May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite® , a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navigating a path to clinical, operational, and financial success.

Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jack Knight - VP, Investor Relations Daniel Burton - CEO & Director Jason Alger - CFO Conference Call Participants Jared Haase - William Blair & Co. Elizabeth Anderson - Evercore ISI Anna Kruszenski - Barclays Capital John Ransom - Raymond James Daniel Grosslight - Citigroup Jenny Shen - BTIG Mitchell Ostrovsky - Guggenheim Securities Stan Berenshteyn - Wells Fargo & Co. Operator Good afternoon, everyone, and welcome to the Health Catalyst First Quarter 2024 Earnings Conference Call. [Operator Instructions].

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.